Concerning the prognostic impact of RAS mutations, in a recent study that included 723 patients with PMF and post-PV or post-ET myelofibrosis (MF), oncogenic NRAS/KRAS mutations conferred a high risk of developing sAML, leading to reduced survival. The gene discussed is NRAS; the disease is essential thrombocythemia.